Srikripa Devarakonda

Stock Analyst at Truist Securities

(0.63)
# 2441
Out of 5,340 analysts
69
Total ratings
33.33%
Success rate
-1.06%
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
ARVN Arvinas
Downgrades: Hold
21 11
6.49 69.49% 1 May 5, 2025
REGN Regeneron Pharmaceut...
Maintains: Buy
975 940
594.5 58.12% 7 Apr 30, 2025
BIIB Biogen
Maintains: Buy
210 199
125.6 58.44% 4 Apr 29, 2025
KROS Keros Therapeutics
Maintains: Buy
43 25
14.07 77.68% 5 Apr 9, 2025
INCY Incyte
Maintains: Hold
74 72
63.23 13.87% 9 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
60 76
44.55 70.59% 2 Mar 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1029 1038
757.24 37.08% 4 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
211 217
184.06 17.9% 3 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 32
22.82 40.23% 1 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
14.79 238.07% 6 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
36 45
30.58 47.16% 4 Nov 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
54 53
30.29 74.98% 3 Nov 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
54 54
1.52 3452.63% 1 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 15
7.55 98.68% 7 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
36
9.56 276.57% 1 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
86 70
30.98 125.95% 4 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
80 60
0.28 21328.57% 2 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
38
n/a n/a 3 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
50 34
n/a n/a 2 Jun 3, 2021